Listed

Sangoma Technologies Corp: Form 40-F for the period ended Jun 30, 2024

Filed with the SEC on Sep 18, 2024 and accepted by EDGAR at Sep 18, 2024, 17:03 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2023-07-01 to 2024-06-30$247.3mifrs-full:Revenue
Cost of revenue12 months2023-07-01 to 2024-06-30$74.5mifrs-full:CostOfSales
Gross profit12 months2023-07-01 to 2024-06-30$172.8mifrs-full:GrossProfit
Income tax12 months2023-07-01 to 2024-06-30−$840.0kifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2023-07-01 to 2024-06-30−$8.7mifrs-full:ProfitLoss
Diluted EPS12 months2023-07-01 to 2024-06-30−$0.26ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2023-07-01 to 2024-06-30−$0.26ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2023-07-01 to 2024-06-30$44.2mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2023-07-01 to 2024-06-30$4.1mifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2024-06-30$16.2mifrs-full:CashAndCashEquivalents
Current assetsAt period end2024-06-30$57.1mifrs-full:CurrentAssets
Total assetsAt period end2024-06-30$400.6mifrs-full:Assets
Current liabilitiesAt period end2024-06-30$60.1mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2024-06-30$140.9mifrs-full:Liabilities
Shareholders' equityAt period end2024-06-30$259.7mifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2024-06-3033,340,159 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001753368-24-000014. Last ingested by Listed: Nov 14, 2026, 18:20 ET. Listed shows no prices and gives no investment advice.